A B S T R A C T Glucagon (0.04-0.09 mg/kg/min) was given intravenously for either 2 or 3 min to eight patients with fasting-induced% hypoglycemia. One child had hepatic phosphorylase deficiency, two children had glucose-6-phosphatase deficiency, two children had debrancher enzyme (amylo-1,6-glucosidase) deficiency, and two children and one adult had decreased hepatic fructose-1,6-diphosphatase (FDPase) activity. Liver biopsy specimens were obtained before and immediately after the glucagon infusion. The glucagon caused a significant increase in the activity of FDPase (from 50± 10.0 to 72±11.7 nmol/mg protein/min) and a significant decrease in the activities of phosphofructokinase (PFK) (from 92±6.1 to 41±8.1 nmol/mg protein/min) and pyruvate kinase (PK) (from 309±39.4 to 165±23.9 nmol/mg protein/min). The glucagon infusion also caused a significant increase in hepatic cyclic AMP concentrations (from 41±2.6 to 233±35.6 pmol/mg protein). Two patients with debrancher enzyme deficiency who had biopsy specimens taken 5 min after the glucagon infusion had persistence of enzyme and cyclic AMP changes for at least 5 min. One child with glucose-6-phosphatase deficiency was given intravenous glucose (150 mg/kg/min) for a period of 5 min after the glucagon infusion and biopsy. The plasma insulin concentration increased from 8 to 152 AU/ml and blood glucose increased from 72 to 204 mg/100 ml. A third 
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Cyclic AMP (0.05 mmol/kg) was injected into the portal vein of adult rats and caused enzyme changes similar to those seen with glucagon administration in humans. Our findings suggest that rapid changes in the activities of PFK, PK, and FDPase are important in the regulation of hepatic glycolysis and gluconeogenesis, respectively, in humans and that cyclic AMP may mediate the glucagon-but probably not the glucose-insulin-induced INTRODUCTION Glucagon and insulin play a central role in the rapid regulation of hepatic gluconeogenesis and glycolysis, but the exact mechanism of their inverse relationship in this regulatory action is not known. The respective rates of glycolysis and gluconeogenesis appear to have more than one mechanism of regulation (2) , and changes in enzyme activities are one possible mechanism of control (3). Other workers (4) (5) (6) (7) (8) open Na pentothal P-C shunt * No complications occurred with any of the biopsies. $ P-C shunt, portacaval venous anastomosis created for the treatment of glycogen storage disease (10).
alteration would not account for the hormone-induced, changes in blood glucose that occur within a matter of minutes after an insulin or glucagon infusion. Data on the short-term effects of hormones on these enzymes are largely unexplained.
In rats we have recently demonstrated that within minutes the intravenous infusion of glucagon or insulin significantly altered the activities of certain enzymes unique to the glycolytic and gluconeogenetic pathways (9) . Glucagon and insulin were reciprocal in their effects on the enzyme activities. Furthermore, the glucagon-induced changes were completely reversed within 3-min after an insulin infusion. Hepatic cyclic AMP concentrations increased 3-to 4-fold within 2 min after glucagon but were not significantly affected by intravenous insulin. After glucagon, insulin did decrease cyclic AMP levels slightly but not enough to account for the alteration of enzyme activities (9) .
This communication extends our observations to man. We studied the acute effects of intravenous glucagon on human hepatic enzyme activities and cyclic AMP concentrations in eight patients with various types of hepatic enzyme deficiencies.
METHODS
Patients. All studies were carried out after obtaining informed consent.' The patients were seven children and one adult who were being treated for fasting-induced hypoglycemia. Biopsies. Percutaneous liver biopsies were performed with the Menghini biopsy needle (1.4 mm). When we were testing for changes in enzyme activities, an initial biopsy specimen was obtained, an intravenous infusion of glucagon (0.04 to 0.09 mg/kg/min) was given with an infusion pump for either 2 or 3 min, and a second biopsy was obtained immediately. Two patients had the second biopsy specimen taken 5 min after the infusion (patients 7 and 8).
One patient with glucose-6-phosphatase deficiency was given an infusion of glucose (150 mg/kg/min) for 5 min after the glucagon administration, and a third biopsy specimen was taken. Liver biopsy specimens were separated into appropriate portions for assay of cyclic AMP (frozen within 10 s in liquid nitrogen), histology, and measurement of the various enzyme activities.
Assays. Phosphofructokinase * Patients undergoing abdominal surgery and without liver disease. Mean and standard error of mean are given. t "Before" indicates that biopsy was performed just before the glucagon infusion, which lasted 3 min in all patients except patient 3. "After" indicates that the second biopsy was obtained immediately after the glucagon infusion except for patients 7 and 8, who had the second biopsy 5 min after the glucagon infusion was completed. § Blood glucose determinations were made at 0 (Before), 2, 5, and 10 min after the glucagon infusion was begun (After).
Immediately after the glucagon infusion, intravenous glucose (150 mg/kg/min) was infused for 5 min.
at room temperature on the supernatant fraction as described previously (11, 12) . The assays were performed simultaneously, under identical conditions for all samples from the same patient. PFK was assayed by the method of Lea and Walker (13) In on patient with hepatic glucose-6-phosphatase deficiency, a 2-min glucagon infusion and biopsy was followed by an intravenous infusion of glucose at a dose of 150 mg/kg/min for 5 min. Fig. 1 shows that there was reversal of the glucagon effect on the enzyme activities, except for PK, by the glucose infusion. Blood insulin values are given in the lower portion of the figure, which shows a several-fold increase over that seen before the glucose infusion. The blood glucose values were 68, 72, and 204 mg/100 ml, which corresponded to the insulin levels of 8, 16 , and 152 AU/ml, respectively.
Unlike the changes in enzyme activities, the glucose infusion was associated with only a minimal decrease in cyclic AMP concentrations. Fig. 2 (4) (5) (6) (7) (8) as well as certain other hepatic enzymes (22, 23) have been reported previously.
In our studies we have investigated the short-term effects of glucagon on three enzymes unique to glycolysis, PFK, PK, and GK, and one enzyme unique to gluconeogenesis, FDPase. PFK, PK, and GK are associated with essentially irreversible reactions and are generally thought to be a major means of controlling the rate of glycolysis. In the case of the gluconeogenetic pathway, pyruvate carboxylase and phosphoenolpyruvate carboxykinase (PEP-CK) appear to be the primary ratelimiting enzymes, but under certain circumstances, FDPase may affect the overall rate of glucose synthesis (24) . This phenomenon is of particular importance in the patients with hypoglycemia due to FDPase deficiency (25, 26) . a TIME, (min) FIGURE 1 Effect of intravenous glucagon followed by intravenous glucose on hepatic enzyme activities, blood insulin (IRI) and cyclic AMP concentrations in one patient with hepatic glucose-6-phosphatase deficiency.
decrease in the activity of PK and a reciprocal increase in the activity of FDPase. PFK activity was measured in four patients and decreased significantly with the glucagon infusion. In three patients, there was a decrease in GK activity after the glucagon infusion. This enzyme was not measured in the remaining patients.
There were no glucagon-induced changes in the activity of the reversible enzyme FDPA. The rapid effects of glucagon on PFK, PK, and FDPase were associated with a significant increase in hepatic cyclic AMP concentrations. In rat experiments, after an epinephrine infusion (0.5-4.0 /.tg/min.) the increase in cyclic AMP concentrations preceded the enzyme changes by 30-60 s and neither effect was inhibited by puromycin or actinomycin-D (27) . Identical studies with glucagon have given similar results (28) These findings are similar to those seen in rats infused with epinephrine (27) or glucagon (28) and then insulin except that in the animals, the glucagon-induced effect on PK was also reversed by the insulin infusion. The changes in cyclic AMP concentrations do not in themselves prove that cyclic AMP is the mediator of the rapid enzyme changes seen after glucagon. However, the cyclic AMP-induced changes in rat liver enzymes do lend support to the concept that cyclic AMIP is directly involved in the glucagon-induced alterations in enzyme activities and my therefore affect the rate of gluconeogenesis and glycolysis within a matter of minutes (30) . The glucose-insulin effect on the changes in enzyme activities do not appear to be mediated by cyclic AMP since the small decrease in cyclic AMP concentrations did not seem sufficient to account for the enzyme changes caused by the glucose infusion in one patient and the epinephrine-insulin or glucagon-insulin infusions in rats. However, we cannot preclude the possibility that insulin alters the ratio between free and bound cyclic AMP so that, although the total cyclic AMP may not change, the active species of cyclic AMP may be diminished.
FDPase activity has been shown to be inhibited by 5 'AMP in vitro (31, 32 (43, 44) may not occur under physiologic conditions. The mechanism whereby these enzyme activities are altered by glucagon is not known. Since a major effect of glucagon is glucose mobilization from the liver to the blood, it is conceivable that in addition to the activation of liver phosphorylase, certain key enzymes in gluconeogenesis are activated by a similar mechanism. Therefore, a unitary hypothesis for the action of glucagon on hepatic release of glucose would involve the simultaneous activation of glycogenolysis and gluconeogenesis, and inactivation of glycogen formation and glycolysis. This mechanism of activation and inactivation of gluconeogenesis and glycolysis, respectively, could possibly involve cyclic AMP and protein kinase(s) in a manner analogous to phosphorylase activation in glycogenolysis and inactivation of glycogen synthetase in glycogen formation (45, 46) . However, no data are presently available to suggest that any of the enzymes measured in this study are activated or inactivated by phosphorylation.
